Literature DB >> 7522857

Effects of antidepressants on the inward current mediated by 5-HT3 receptors in rat nodose ganglion neurones.

P Fan1.   

Abstract

1. Effects of three different categories of antidepressants, imipramine (tricyclic), fluoxetine (selective 5-hydroxytryptamine (5-HT) uptake inhibitor), phenelzine and iproniazid (monoamine oxidase (MAO) inhibitor) on the inward current mediated by 5-HT3 receptors were investigated in rat nodose ganglion neurones. The whole-cell patch-clamp technique was used for recording the 5-HT current. 2. All the antidepressants tested inhibited the peak 5-HT current. The inhibition gradually reached a steady level and the recovery was incomplete when antidepressants were removed. IC50 values for imipramine, fluoxetine and phenelzine were 0.54 microM, 1.3 microM and 4.2 microM respectively. The correspondent Hill coefficients were 0.9, 0.87 and 0.92. 3. The antidepressants examined increased the rate of 5-HT current desensitization. IC50 values for imipramine, fluoxetine and phenelzine on the decrease in desensitization time constant were 0.11 microM, 0.18 microM and 2.4 microM respectively. The correspondent Hill coefficients were 0.9, 1.14 and 1.06. 4. Intracellular applications of the protein kinase inhibitor, H-7 (100 microM), GDP-beta-S (2 mM) and the calcium chelator BAPTA (20 mM) did not affect the 5-HT current and the actions of antidepressants on 5-HT current. 5. These results suggest that the 5-HT3 receptor is an acting site for the therapeutic use of antidepressants. The present observation is also helpful in explaining the analgesic effect of antidepressants seen in pain clinics.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7522857      PMCID: PMC1910226          DOI: 10.1111/j.1476-5381.1994.tb13140.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

Review 1.  5-HT3 receptors.

Authors:  M B Tyers
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

2.  Activation and desensitization of the 5-HT3 receptor in a rat glioma x mouse neuroblastoma hybrid cell.

Authors:  J L Yakel; X M Shao; M B Jackson
Journal:  J Physiol       Date:  1991-05       Impact factor: 5.182

3.  Interaction of psychotropic drugs with central 5-HT3 recognition sites: fact or artifact?

Authors:  D Hoyer; H Gozlan; F Bolanos; L E Schechter; M Hamon
Journal:  Eur J Pharmacol       Date:  1989-11-14       Impact factor: 4.432

4.  Antidepressant interactions with 5-hydroxytryptamine3 receptor binding sites.

Authors:  A W Schmidt; S J Peroutka
Journal:  Eur J Pharmacol       Date:  1989-04-25       Impact factor: 4.432

5.  5-HT3 receptors mediate rapid responses in cultured hippocampus and a clonal cell line.

Authors:  J L Yakel; M B Jackson
Journal:  Neuron       Date:  1988-09       Impact factor: 17.173

6.  Antagonism by antidepressants of serotonin S1 and S2 receptors of normal human brain in vitro.

Authors:  T J Wander; A Nelson; H Okazaki; E Richelson
Journal:  Eur J Pharmacol       Date:  1986-12-16       Impact factor: 4.432

7.  Peripherally administered serotonin 5-HT3 receptor antagonists reduce inflammatory pain in rats.

Authors:  J Giordano; L V Rogers
Journal:  Eur J Pharmacol       Date:  1989-10-24       Impact factor: 4.432

8.  Blockade of the flare response to intradermal 5-hydroxytryptamine in man by MDL 72.222, a selective antagonist at neuronal 5-hydroxytryptamine receptors.

Authors:  J M Orwin; J R Fozard
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Differential analgesic actions of serotonin 5-HT3 receptor antagonists in the mouse.

Authors:  J Giordano; J Dyche
Journal:  Neuropharmacology       Date:  1989-04       Impact factor: 5.250

Review 10.  Fluoxetine, a selective inhibitor of serotonin uptake.

Authors:  R W Fuller; D T Wong; D W Robertson
Journal:  Med Res Rev       Date:  1991-01       Impact factor: 12.944

View more
  14 in total

1.  The GABAergic deficit hypothesis of major depressive disorder.

Authors:  B Luscher; Q Shen; N Sahir
Journal:  Mol Psychiatry       Date:  2010-11-16       Impact factor: 15.992

Review 2.  The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications.

Authors:  A J Greenshaw; P H Silverstone
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

3.  Inhibition of G protein-activated inwardly rectifying K+ channels by fluoxetine (Prozac).

Authors:  Toru Kobayashi; Kazuo Washiyama; Kazutaka Ikeda
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

Review 4.  Allosteric modulation of the 5-HT(3) receptor.

Authors:  Paul A Davies
Journal:  Curr Opin Pharmacol       Date:  2011-02-20       Impact factor: 5.547

5.  Response of Htr3a knockout mice to antidepressant treatment and chronic stress.

Authors:  Vincent Martin; Armance Riffaud; Tevrasamy Marday; Charly Brouillard; Bernard Franc; Jean-Pol Tassin; Caroline Sevoz-Couche; Raymond Mongeau; Laurence Lanfumey
Journal:  Br J Pharmacol       Date:  2017-07-05       Impact factor: 8.739

6.  Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac).

Authors:  J García-Colunga; J N Awad; R Miledi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

7.  In vitro inhibition of recombinant ligand-gated ion channels by high concentrations of milnacipran.

Authors:  Kazuyoshi Ueta; Takahiro Suzuki; Ichiro Uchida; Takashi Mashimo
Journal:  Psychopharmacology (Berl)       Date:  2004-03-02       Impact factor: 4.530

8.  Electrophysiological consequences of ligand binding to the desensitized 5-HT3 receptor in mammalian NG108-15 cells.

Authors:  J T Bartrup; N R Newberry
Journal:  J Physiol       Date:  1996-02-01       Impact factor: 5.182

9.  The interaction of antidepressant drugs with central and peripheral (enteric) 5-HT3 and 5-HT4 receptors.

Authors:  A Lucchelli; M G Santagostino-Barbone; A Barbieri; S M Candura; M Tonini
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

10.  Pharmacodynamics of memantine: an update.

Authors:  G Rammes; W Danysz; C G Parsons
Journal:  Curr Neuropharmacol       Date:  2008-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.